In-House Insights: Investment Diligence for a Healthcare VC

August 20, 2021 | BY

Vincent Chow

Edward Tung, legal counsel for Hong Kong-based venture capital firm ORI Capital, discusses the growing importance of ESG, the rise of special purpose acquisition companies (SPACs) and the advantage of having scientific expertise when representing healthcare and biotechnology companies.

Edward Tung, legal counsel at ORI Capital Edward Tung, legal counsel at ORI Capital/Courtesy photo

Edward Tung is legal counsel, head of compliance and chair of the risk management committee for ORI Capital, a Hong Kong-based venture capital firm launched in 2015 that focuses on investing in innovative healthcare companies globally. ORI Healthcare Fund has a fund size of $200 million, while ORI Healthcare Fund II has a target fund size of $400 million. Prior to joining the firm in 2019, Tung was an associate at the Hong Kong-based international law firm Deacons. We asked him about the growing importance of ESG, the rise of special purpose acquisition companies (SPACs) in the United States and his decision to switch from working in science to working in the law.

This Q&A has been lightly edited for clarity and brevity.

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]